Abstract
Since the earliest descriptions of Alzheimer ’ s disease (AD), the presence of senile plaques (SP) and neurofibrillary tangles (NFT) have been regarded as the typical pathological hallmarks of the disease. Studies over the last twenty years, however, have reported a considerable degree of heterogeneity within the AD phenotype and as a consequence, an overlap between the pathological features of AD not only with normal aging, but also with disorders related to AD. This review discusses: 1) the degree of heterogeneity within AD, 2) the concept of an ‘interface’ between disorders, 3) the nature and degree of the interface between AD and normal aging, vascular dementia (VD), the tauopathies, synucleinopathies, and prion disease, and 4) whether the original status of AD should be retained or whether AD, normal aging, and the related disorders should be regarded as representing a ‘continuum’ of neuropathological change.
Keywords: Alzheimer's disease (AD), brain lesion, continuum, disease heterogeneity, tauopathy, synucleinopathy, prion disease
Current Aging Science
Title: The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders
Volume: 1 Issue: 2
Author(s): R. A. Armstrong
Affiliation:
Keywords: Alzheimer's disease (AD), brain lesion, continuum, disease heterogeneity, tauopathy, synucleinopathy, prion disease
Abstract: Since the earliest descriptions of Alzheimer ’ s disease (AD), the presence of senile plaques (SP) and neurofibrillary tangles (NFT) have been regarded as the typical pathological hallmarks of the disease. Studies over the last twenty years, however, have reported a considerable degree of heterogeneity within the AD phenotype and as a consequence, an overlap between the pathological features of AD not only with normal aging, but also with disorders related to AD. This review discusses: 1) the degree of heterogeneity within AD, 2) the concept of an ‘interface’ between disorders, 3) the nature and degree of the interface between AD and normal aging, vascular dementia (VD), the tauopathies, synucleinopathies, and prion disease, and 4) whether the original status of AD should be retained or whether AD, normal aging, and the related disorders should be regarded as representing a ‘continuum’ of neuropathological change.
Export Options
About this article
Cite this article as:
Armstrong A. R., The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders, Current Aging Science 2008; 1 (2) . https://dx.doi.org/10.2174/1874609810801020122
DOI https://dx.doi.org/10.2174/1874609810801020122 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety Cerebrospinal-fluid Alzheimer’s Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson’s Disease Patients
CNS & Neurological Disorders - Drug Targets Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology Commentary [Research Highlights (Making Sense Out of Antisense in Huntington’s Disease)]
CNS & Neurological Disorders - Drug Targets Mechanisms of HIV Transcriptional Regulation by Drugs of Abuse
Current HIV Research Serotonin (5-HT) in the Regulation of Depression-Related Emotionality: Insight from 5-HT Transporter and Tryptophan Hydroxylase-2 Knockout Mouse Models
Current Drug Targets Memorization Test and Resting State EEG Components in Mild and Subjective Cognitive Impairment
Current Alzheimer Research Melatonin Receptor as a Drug Target for Neuroprotection
Current Molecular Pharmacology Oxidative Stress in Traumatic Brain Injury
Current Medicinal Chemistry Physical Inactivity is Liable to the Increased Cardiovascular Risk and Impaired Cognitive Profile
Current Alzheimer Research Computerized Methods in the Assessment and Prediction of Dementia
Current Alzheimer Research Editorial - Advances of Alzheimers Disease Research: Crossroad of Basic and Translational Studies
Current Alzheimer Research Hydrolytic Activity of Amyloid-beta and its Inhibition with Short Peptides
Current Medicinal Chemistry - Central Nervous System Agents Psychological Problems in Female Fragile X Premutations Carriers
Current Psychiatry Reviews Calmodulin in Complex with Proteins and Small Molecule Ligands: Operating with the Element of Surprise; Implications for Structure-Based Drug Design
Current Computer-Aided Drug Design Insulin Resistance as Common Molecular Denominator Linking Obesity to Alzheimer’s Disease
Current Alzheimer Research Plasma Clusterin as a Potential Biomarker for Alzheimer’s Disease-A Systematic Review and Meta-analysis
Current Alzheimer Research Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson`s Disease
CNS & Neurological Disorders - Drug Targets The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases
Current Neuropharmacology A Speech Recognition-based Solution for the Automatic Detection of Mild Cognitive Impairment from Spontaneous Speech
Current Alzheimer Research